Hims & Hers Health Drops 14% on Securities Fraud Lawsuit
Hims & Hers Health fell over 14% after Kahn Swick & Foti filed a securities fraud class action alleging deceptive billing and privacy practices, with a partial 10% rebound leaving the stock's near-ter
Hims & Hers Health Drops 14% on Securities Fraud Lawsuit
NEW YORK, October 10 —
Hims & Hers Health, Inc. (HIMS) dropped more than 14% after a securities fraud class action alleged deceptive billing and privacy practices.
- Stock fell over 14% on lawsuit disclosure; a ~10% partial rebound left shares still materially below pre-news levels
- 41.9x fwd P/E on $-0.64 trailing EPS, the entire valuation is a bet that subscriber growth holds
- Lead plaintiff deadline and any company response or settlement disclosure are the next price catalysts
The Lawsuit Strikes at Subscription Trust, Not the Edges
Kahn Swick & Foti, LLC filed the securities fraud class action alleging Hims & Hers Health, Inc. (HIMS) misled investors about its billing and privacy practices. Unlike a peripheral compliance fine, this allegation cuts to the core of what HIMS sells: a seamless, auto-renewing subscription where patients trust the company with both health data and a credit card on file. If patients believe they were billed deceptively, churn accelerates before litigation even settles. The gap-down visible in the chart reflects that subscriber-retention risk being priced in for the first time.
The privacy claim adds a separate front. Telehealth platforms handling health data and prescriptions face HIPAA scrutiny independent of any securities suit, meaning HIMS could be managing two parallel legal exposures simultaneously.
27.3% Short Float Pre-Loaded the Selloff
Over a quarter of HIMS's float was already sold short before this week, and the class action was precisely the catalyst bears needed to trigger stop-loss selling from longs. A securities fraud suit of this structure validates the short thesis without requiring a verdict. With 27.3% of float short, one share in four was already betting on more pain. That drop is partly fundamentals, partly a pre-loaded unwind.
The ~10% rebound is partly short covering. Covering-driven bounces can look like reversals; they rarely are when the underlying legal risk remains unresolved. Do not confuse mechanical buying with cleared risk.
$849mn FCF Gives Bulls Somewhere Concrete to Stand
HIMS generated $849mn in trailing FCF on $2.6bn TTM revenue growing 38.2% YoY. Negative GAAP EPS at $-0.64 reflects subscriber acquisition spending; the company is investing capital, not consuming it. That distinction matters when sizing the lawsuit's actual damage. A settlement, even a sizeable one, does not break the model if subscriber growth continues at this pace.
At 41.9x forward earnings, however, the stock prices in near-perfection. Use the DCF calculator to stress-test what any slowdown in subscriber growth does to the current $30.92 price on a name with no earnings cushion.
Subscriber Adds in Q4 Are the Only Number That Settles This
Watch net subscriber adds in the Q4 report. If billing allegations are scaring patients off, that number slows. If it holds, the lawsuit looks manageable and the initial drop looks like an overreaction already half-corrected. The stock at 41.9x forward earnings has zero tolerance for a growth miss. Net subscriber retention is the specific metric that would prove the damage permanent, and it will not be visible until Q4 results land. Monitor the live valuation picture at HIMS fundamentals as the lead plaintiff process develops.
A full Basis Report analysis with a HOLD rating is available at the HIMS deep-dive report.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Hims & Hers Health faces a securities fraud class action lawsuit alleging deceptive privacy and billing practices, contributing to a 14%+ stock decline.